Autism Spectrum Disorder Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Global Autism Spectrum Disorders Treatment Market is Segmented by Drug Class (Antipsychotic Drugs, SSRIs/Antidepressants, Stimulants, and Other Drug Classes), By Type (Autistic Disorder, Asperger’s Syndrome, and Other Types), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

autism spectrum disorders treatment market
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: >7 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The autism spectrum disorders treatment market is expected to register a CAGR of more than 7% over the forecast period, 2022-2027.

The COVID-19 pandemic has significantly impacted the autism disorders treatment market. This can be attributed to the fact that the pandemic caused supply chain disruptions in the pharmaceutical industry which led to problems in seeking treatment for autism spectrum disorders. Thus, the pandemic had a short-term negative impact on the market. In addition, as per a June 2021 published article titled, "Leveraging Technology for the Wellbeing of Individuals With Autism Spectrum Disorder and Their Families During Covid-19", one-way technology can be used during the pandemic for families with autism spectrum disorder (ASD) is through telehealth, which refers to providing various remote services electronically, such as patient care, education, and monitoring. Thus, telehealth has aided in meeting the rising demand for autism spectrum disorder treatment, thereby contributing to the market growth. Also, as per a December 2021 published study titled, "Coping with autism during lockdown period of the COVID-19 pandemic", the COVID-19 pandemic disrupted routines, triggered behavioral issues in individuals with ASD, and impacted the coping skills of both individuals and families, along with the mental health and well-being of the family. Such studies indicate the significantly high demand for autism spectrum disorders treatment amid the pandemic, thereby depicting an overall positive impact on the market.

The growth of the market can be attributed to the factors such as the increasing burden of autism spectrum disorder worldwide, rising awareness about the condition and available treatment options for autism spectrum disorder, as well as the growing number of investments in autism spectrum disorder.

For instance, as per a March 2022 update by the World Health Organization (WHO), about one in 100 children has autism. In addition, as per an October 2021 published study titled "Prevalence of Autism Spectrum Disorder and Co-morbidities in Children and Adolescents: A Systematic Literature Review," thirteen studies on the prevalence of autism spectrum disorder and 33 on the prevalence of co-morbidities were included. Prevalence of ASD was 1.70 and 1.85% in the United States in children aged 4 and 8 years, respectively, while the prevalence in Europe ranged between 0.38 and 1.55%. Additionally, current evidence is supportive of a global increase in autism spectrum disorder prevalence over the past years. However, the growing number of investments is also a major factor driving the market growth. For instance, in November 2021, Yamo Pharmaceuticals, LLC, reported that The Autism Impact Fund had made a capital investment in Yamo to support a Phase II study of L1-79 in adolescents and adults with an autism spectrum disorder. L1-79, the company's lead candidate, is a tyrosine hydroxylase inhibitor designed to modulate the catecholaminergic pathways implicated in autism spectrum disorder (ASD) and thus impact the socialization and communication symptoms in individuals with ASD.

However, the high cost of autism spectrum disorder treatment and diagnosis, as well as stringent regulations about product approval, are the major factors hindering the market growth.

Scope of the Report

As per the scope of the report, autism spectrum disorders constitute a diverse group of conditions related to the development of the brain and are characterized by some degree of difficulty with social interaction and communication. The market is segmented by drug class (antipsychotic drugs, selective serotonin reuptake inhibitors (SSRIs)/antidepressants, stimulants, and other drug classes), by type (autistic disorder, Asperger’s Syndrome, and other types), by distribution channel (hospital pharmacies, drug stores and retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Drug Class
Antipsychotic Drugs
SSRIs/Antidepressants
Stimulants
Other Drug Classes
By Type
Autistic Disorder
Asperger's Sydrome
Other Types
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Pharmacies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle- East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Autistic Disorder Segment is Expected to Hold a Major Market Share in the Autism Spectrum Disorders Treatment Market

By type, the autistic disorders segment is expected to hold a significant market share attributing to the factors such as increasing research and development as well as the initiatives undertaken by the market players and government. People with autistic disorder usually have significant language delays, social and communication challenges, and unusual behaviors and interests, and people with autistic disorder also have an intellectual disability.

In November 2021, a group of Indian researchers developed a compound called “6BIO” that can provide a better method to treat Autism Spectrum Disorder (ASD). They have determined the potency of the compound in a pre-clinical mice model. This is the first compound that has been proved in pre-clinical evaluation to have the potential for improving daily activities like learning and recollecting new tasks in patients with ASD/ Intellectual disability (ID).

In addition, in October 2021, Axial Therapeutics obtained funding for a Phase II autism trial with USD 37 million Series C to further work on neurological diseases.

Thus, due to the above-mentioned factors, the market is expected to witness significant growth over the forecast period.

autism spectrum disorders treatment market share

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

Within North America, the United States has held a significant share of the market. The major factors contributing to the market growth are the burden of autism spectrum disorders, increasing research and development as well as growing number of investments.

For instance, as per a March 2022 update by the Centers for Disease Control and Prevention (CDC), about 1 in 44 children has been identified with autism spectrum disorder (ASD). Thus, there is a growing need for autism spectrum disorder treatment in the country.

The increasing number of initiatives undertaken by the market players is contributing to the market growth. For instance, in April 2022, XRHealth, the gateway to the healthcare metaverse, reported that their virtual/augmented reality therapy is available in the United States to treat patients with autism. Such developments are expected to fuel the development of drugs, thereby proliferating market growth.

In addition, in June 2021, Cognoa, a pediatric behavioral health company developing diagnostic and therapeutic solutions for children living with behavioral health conditions, reported that the United States Food and Drug Administration (FDA) had granted the company's De Novo classification request for its autism diagnosis aid.

Thus, due to the above-mentioned factors, the market is expected to witness significant growth over the forecast period.

autism spectrum disorders treatment industry

Competitive Landscape

The autism spectrum disorders treatment market is competitive and nearly consolidated with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are PaxMedica, Yamo Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd, and Q BioMed Inc., among other players.

Recent Developments

  • In August 2022, Bened Life released the first gut-brain medical probiotic, Neuralli. Made in the United States and utilizing the patented probiotic strain L. plantarum PS128, Neuralli is designed to promote mental health and support neurological conditions including but not limited to Parkinson’s disease (PD) and autism spectrum disorder (ASD).
  • In March 2022, STALICLA, a Swiss clinical-stage biotech company leading omics-based drug development for patients with neurodevelopmental disorders (NDDs), reported the highly successful completion of the phase 1b trials for its lead drug candidate STP1. These clinical data clear the way for the first application of STALICLA’s precision medicine discovery platform in autism spectrum disorders.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Burden of Autism Spectrum Disorder (ASD) Worldwide

      2. 4.2.2 Rising Awareness Pertaining ASD and Growing Number of Investments

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Autism Spectrum Disorder Treatment and Diagnosis

      2. 4.3.2 Stringent Regulations Pertaining to Product Approval

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Drug Class

      1. 5.1.1 Antipsychotic Drugs

      2. 5.1.2 SSRIs/Antidepressants

      3. 5.1.3 Stimulants

      4. 5.1.4 Other Drug Classes

    2. 5.2 By Type

      1. 5.2.1 Autistic Disorder

      2. 5.2.2 Asperger's Sydrome

      3. 5.2.3 Other Types

    3. 5.3 By Distribution Channel

      1. 5.3.1 Hospital Pharmacies

      2. 5.3.2 Drug Stores and Retail Pharmacies

      3. 5.3.3 Online Pharmacies

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle- East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Q BioMed Inc.

      2. 6.1.2 PaxMedica

      3. 6.1.3 Yamo Pharmaceuticals

      4. 6.1.4 Otsuka Pharmaceutical Co., Ltd.

      5. 6.1.5 F. Hoffmann-La Roche Ltd

      6. 6.1.6 Curemark, LLC

      7. 6.1.7 Zynerba Pharmaceuticals, Inc

      8. 6.1.8 Axial Therapeutics

      9. 6.1.9 Novartis AG

      10. 6.1.10 STALICLA

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Autism Spectrum Disorders Treatment Market market is studied from 2019 - 2027.

The Global Autism Spectrum Disorders Treatment Market is growing at a CAGR of >7% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

PaxMedica, Yamo Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd, Q BioMed Inc. are the major companies operating in Global Autism Spectrum Disorders Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!